Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024

SELL
$902.69 - $993.35 $622,856 - $685,411
-690 Reduced 70.26%
292 $281,000
Q4 2023

Feb 12, 2024

BUY
$775.18 - $881.7 $186,043 - $211,608
240 Added 32.35%
982 $862,000
Q3 2023

Nov 02, 2023

SELL
$692.45 - $844.37 $860,715 - $1.05 Million
-1,243 Reduced 62.62%
742 $610,000
Q2 2023

Jul 17, 2023

BUY
$700.03 - $830.35 $410,217 - $486,585
586 Added 41.89%
1,985 $1.43 Million
Q4 2022

Feb 09, 2023

SELL
$705.89 - $766.39 $534,358 - $580,157
-757 Reduced 35.11%
1,399 $1.01 Million
Q3 2022

Nov 10, 2022

SELL
$573.97 - $724.32 $357,583 - $451,251
-623 Reduced 22.42%
2,156 $1.49 Million
Q2 2022

Aug 03, 2022

SELL
$548.35 - $738.84 $405,779 - $546,741
-740 Reduced 21.03%
2,779 $1.64 Million
Q1 2022

May 03, 2022

SELL
$595.12 - $698.43 $7,141 - $8,381
-12 Reduced 0.34%
3,519 $2.46 Million
Q4 2021

Feb 01, 2022

BUY
$543.48 - $670.97 $982,068 - $1.21 Million
1,807 Added 104.81%
3,531 $2.23 Million
Q3 2021

Oct 08, 2021

SELL
$574.03 - $680.96 $12,628 - $14,981
-22 Reduced 1.26%
1,724 $1.04 Million
Q2 2021

Aug 05, 2021

SELL
$472.8 - $558.54 $211,341 - $249,667
-447 Reduced 20.38%
1,746 $975,000
Q1 2021

Apr 14, 2021

BUY
$446.73 - $548.2 $515,973 - $633,171
1,155 Added 111.27%
2,193 $1.04 Million
Q1 2021

Apr 13, 2021

SELL
$446.73 - $548.2 $19.7 Million - $24.2 Million
-44,193 Reduced 97.71%
1,038 $491,000
Q4 2020

Feb 08, 2021

BUY
$478.3 - $607.98 $471,603 - $599,468
986 Added 2.23%
45,231 $21.9 Million
Q3 2020

Nov 12, 2020

BUY
$544.75 - $658.21 $1.78 Million - $2.15 Million
3,272 Added 7.99%
44,245 $24.8 Million
Q2 2020

Jul 22, 2020

BUY
$493.32 - $643.92 $214,594 - $280,105
435 Added 1.07%
40,973 $25.6 Million
Q1 2020

May 22, 2020

BUY
$336.18 - $494.43 $8.17 Million - $12 Million
24,298 Added 149.62%
40,538 $19.8 Million
Q1 2020

May 13, 2020

SELL
$336.18 - $494.43 $6.68 Million - $9.83 Million
-19,877 Reduced 55.04%
16,240 $444,000
Q4 2019

Feb 12, 2020

BUY
$274.13 - $376.51 $4.74 Million - $6.51 Million
17,295 Added 91.89%
36,117 $13.6 Million
Q3 2019

Nov 07, 2019

BUY
$273.46 - $318.39 $1.26 Million - $1.47 Million
4,616 Added 32.49%
18,822 $5.22 Million
Q2 2019

Jul 19, 2019

BUY
$299.6 - $414.82 $3.09 Million - $4.28 Million
10,319 Added 265.47%
14,206 $4.45 Million
Q1 2019

May 14, 2019

BUY
$372.08 - $439.57 $19,348 - $22,857
52 Added 1.36%
3,887 $1.6 Million
Q4 2018

Apr 29, 2019

SELL
$335.82 - $403.04 $651,154 - $781,494
-1,939 Reduced 33.58%
3,835 $1.43 Million
Q4 2018

Feb 07, 2019

BUY
$335.82 - $403.04 $436,230 - $523,548
1,299 Added 29.03%
5,774 $2.16 Million
Q3 2018

Nov 13, 2018

BUY
$351.14 - $408.51 $3,511 - $4,085
10 Added 0.22%
4,475 $1.81 Million
Q2 2018

Aug 08, 2018

BUY
$284.6 - $344.99 $115,263 - $139,720
405 Added 9.98%
4,465 $1.54 Million
Q1 2018

May 02, 2018

BUY
$315.82 - $393.78 $39,161 - $48,828
124 Added 3.15%
4,060 $1.4 Million
Q4 2017

Feb 09, 2018

BUY
$358.63 - $469.95 $24,386 - $31,956
68 Added 1.76%
3,936 $1.48 Million
Q3 2017

Nov 03, 2017

SELL
$431.38 - $504.0 $186,356 - $217,728
-432 Reduced 10.05%
3,868 $1.73 Million
Q2 2017

Aug 11, 2017

BUY
N/A
4,300
4,300 $2.11 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $75.2B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track F Dx Advisors, Inc. Portfolio

Follow F Dx Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of F Dx Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on F Dx Advisors, Inc. with notifications on news.